RU2013121744A - Лечение рака/ингибирование метастазирования - Google Patents
Лечение рака/ингибирование метастазирования Download PDFInfo
- Publication number
- RU2013121744A RU2013121744A RU2013121744/15A RU2013121744A RU2013121744A RU 2013121744 A RU2013121744 A RU 2013121744A RU 2013121744/15 A RU2013121744/15 A RU 2013121744/15A RU 2013121744 A RU2013121744 A RU 2013121744A RU 2013121744 A RU2013121744 A RU 2013121744A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- reducing
- metastatic behavior
- behavior according
- preventing metastatic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 37
- 201000011510 cancer Diseases 0.000 title claims abstract 16
- 206010027476 Metastases Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 230000008883 metastatic behaviour Effects 0.000 claims abstract 53
- 238000000034 method Methods 0.000 claims abstract 48
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims abstract 15
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims abstract 15
- 230000004899 motility Effects 0.000 claims abstract 6
- 230000005012 migration Effects 0.000 claims abstract 5
- 238000013508 migration Methods 0.000 claims abstract 5
- 230000000694 effects Effects 0.000 claims abstract 4
- 210000001519 tissue Anatomy 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims 6
- 229960000213 ranolazine Drugs 0.000 claims 6
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 4
- 210000002469 basement membrane Anatomy 0.000 claims 4
- 229960004181 riluzole Drugs 0.000 claims 4
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 230000000431 effect on proliferation Effects 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2010/001908 WO2012049440A1 (en) | 2010-10-13 | 2010-10-13 | Treatment of cancer/inhibition of metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013121744A true RU2013121744A (ru) | 2014-11-20 |
Family
ID=44022817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013121744/15A RU2013121744A (ru) | 2010-10-13 | 2010-10-13 | Лечение рака/ингибирование метастазирования |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130203764A1 (https=) |
| EP (4) | EP2627321A1 (https=) |
| JP (1) | JP2013539778A (https=) |
| KR (1) | KR20140032346A (https=) |
| CN (2) | CN112755029A (https=) |
| AU (2) | AU2010362412A1 (https=) |
| BR (1) | BR112013009086A2 (https=) |
| CA (1) | CA2851694C (https=) |
| DK (1) | DK3132791T3 (https=) |
| IL (1) | IL225689A0 (https=) |
| RU (1) | RU2013121744A (https=) |
| SG (1) | SG189352A1 (https=) |
| WO (1) | WO2012049440A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013009086A2 (pt) | 2010-10-13 | 2016-07-26 | Mustafa Bilgin Ali Djamgoz | tratamento de câncer/inibição de metástase |
| WO2013123403A1 (en) * | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| WO2017091574A1 (en) * | 2015-11-25 | 2017-06-01 | Health Research, Inc. | Riluzole and riluzole drug combinations for the treatment of prostate cancer |
| JP6465306B2 (ja) * | 2016-02-04 | 2019-02-06 | セレックス・オンコロジー・リミテッド | 癌の治療／転移の阻害 |
| LT3458053T (lt) * | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
| AU2018218341B2 (en) * | 2017-02-10 | 2023-07-06 | Celex Oncology Innovations Limited | Treatment of cancer and inhibition of metastasis |
| US20200123544A1 (en) * | 2018-10-22 | 2020-04-23 | Celex Oncology Innovations Limited | Gene therapy targeting the neonatal form of nav1.5 for treating cancer |
| AU2020370748B2 (en) * | 2019-10-24 | 2025-08-21 | Celex Oncology Innovations Limited | Combination treatments for cancer |
| US20230062361A1 (en) | 2020-01-21 | 2023-03-02 | Celex Oncology Innovations Limited | Monoclonal antibodies against neonatal nav1.5 |
| US20230139204A1 (en) | 2020-03-09 | 2023-05-04 | Celex Oncology Innovations Limited | Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells |
| EP4176880A4 (en) * | 2020-07-01 | 2024-07-03 | New Cancer Cure - Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A 3-KETOACYL-COA THIOLASE INHIBITOR AND AN INHIBITOR OF CARNITINE ACYLCARNITINE TRANSPORTERS |
| AU2024357729A1 (en) | 2023-10-12 | 2026-04-09 | Celex Oncology Innovations Limited | Treatment of metastatic or invasive brain cancer |
| WO2025252860A1 (en) | 2024-06-04 | 2025-12-11 | Celex Oncology Innovations Limited | Ranolazine enantiomer for use in cancer treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003088915A2 (en) * | 2002-04-18 | 2003-10-30 | University Of Virginia Patent Foundation | Novel sodium channel blockers |
| WO2004062604A2 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| US8835473B2 (en) * | 2004-04-16 | 2014-09-16 | Rutgers, The State University Of New Jersey | Methods and compositions for treating cancer |
| ES2691411T3 (es) | 2006-03-27 | 2018-11-27 | Wex Medical Limited | Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia |
| CA2716321A1 (en) * | 2008-02-21 | 2009-08-27 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| WO2010033581A1 (en) * | 2008-09-16 | 2010-03-25 | University Of Washington | Molecular modulators of the wnt/beta-catenin pathway |
| BR112013009086A2 (pt) * | 2010-10-13 | 2016-07-26 | Mustafa Bilgin Ali Djamgoz | tratamento de câncer/inibição de metástase |
-
2010
- 2010-10-13 BR BR112013009086A patent/BR112013009086A2/pt not_active IP Right Cessation
- 2010-10-13 EP EP10776791.5A patent/EP2627321A1/en not_active Withdrawn
- 2010-10-13 CN CN202110087549.9A patent/CN112755029A/zh active Pending
- 2010-10-13 EP EP19211429.6A patent/EP3653206A1/en not_active Ceased
- 2010-10-13 CN CN2010800703488A patent/CN103370060A/zh active Pending
- 2010-10-13 EP EP25174138.5A patent/EP4640281A3/en active Pending
- 2010-10-13 CA CA2851694A patent/CA2851694C/en active Active
- 2010-10-13 SG SG2013026968A patent/SG189352A1/en unknown
- 2010-10-13 EP EP16020321.2A patent/EP3132791B1/en active Active
- 2010-10-13 KR KR1020137012365A patent/KR20140032346A/ko not_active Withdrawn
- 2010-10-13 RU RU2013121744/15A patent/RU2013121744A/ru not_active Application Discontinuation
- 2010-10-13 DK DK16020321.2T patent/DK3132791T3/da active
- 2010-10-13 US US13/879,146 patent/US20130203764A1/en not_active Abandoned
- 2010-10-13 AU AU2010362412A patent/AU2010362412A1/en not_active Abandoned
- 2010-10-13 JP JP2013533265A patent/JP2013539778A/ja active Pending
- 2010-10-13 WO PCT/GB2010/001908 patent/WO2012049440A1/en not_active Ceased
-
2013
- 2013-04-10 IL IL225689A patent/IL225689A0/en unknown
-
2015
- 2015-10-13 US US14/881,952 patent/US20160096812A1/en not_active Abandoned
-
2017
- 2017-04-06 AU AU2017202267A patent/AU2017202267B2/en active Active
-
2018
- 2018-06-07 US US16/002,555 patent/US20180346431A1/en not_active Abandoned
-
2019
- 2019-09-19 US US16/576,178 patent/US11634398B2/en active Active
-
2022
- 2022-12-19 US US18/068,263 patent/US12534444B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012049440A1 (en) | 2012-04-19 |
| US20160096812A1 (en) | 2016-04-07 |
| CA2851694C (en) | 2019-02-26 |
| AU2017202267A1 (en) | 2017-04-27 |
| US20200017457A1 (en) | 2020-01-16 |
| IL225689A0 (en) | 2013-06-27 |
| US20130203764A1 (en) | 2013-08-08 |
| EP3653206A1 (en) | 2020-05-20 |
| JP2013539778A (ja) | 2013-10-28 |
| EP2627321A1 (en) | 2013-08-21 |
| BR112013009086A2 (pt) | 2016-07-26 |
| EP3132791B1 (en) | 2019-11-27 |
| EP3132791A1 (en) | 2017-02-22 |
| US11634398B2 (en) | 2023-04-25 |
| AU2010362412A1 (en) | 2013-05-30 |
| US20230202994A1 (en) | 2023-06-29 |
| EP4640281A3 (en) | 2026-01-07 |
| US12534444B2 (en) | 2026-01-27 |
| AU2017202267B2 (en) | 2019-01-24 |
| DK3132791T3 (da) | 2020-03-09 |
| CN112755029A (zh) | 2021-05-07 |
| US20180346431A1 (en) | 2018-12-06 |
| CN103370060A (zh) | 2013-10-23 |
| EP4640281A2 (en) | 2025-10-29 |
| SG189352A1 (en) | 2013-05-31 |
| KR20140032346A (ko) | 2014-03-14 |
| CA2851694A1 (en) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013121744A (ru) | Лечение рака/ингибирование метастазирования | |
| Dziegielewska et al. | T-type calcium channels blockers as new tools in cancer therapies | |
| Afsharimani et al. | Morphine and breast tumor metastasis: the role of matrix-degrading enzymes | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
| UY28081A1 (es) | Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular | |
| EA201290901A1 (ru) | Фитоканнабиноиды для лечения злокачественной опухоли | |
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| RU2016117729A (ru) | Терапия рака путем таргетинга покоящихся раковых клеток | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| Qu et al. | Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| AU2011323155A8 (en) | Combination therapy for prostate cancer using botanical compositions and bicalutamide | |
| Wang et al. | Effect of a rosmarinic acid supplemented hemodialysis fluid on inflammation of human vascular endothelial cells | |
| MX2025006565A (es) | Terapia contra el cancer con capivasertib y fulvestrant | |
| Damstra et al. | Cancer‐related secondary lymphoedema due to cutaneous lymphangitis carcinomatosa: clinical presentations and review of literature | |
| Lu et al. | Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis | |
| Arribas et al. | Targeting the epigenome and the cell signaling as novel therapeutic approaches for splenic marginal zone lymphoma | |
| EA200601471A1 (ru) | Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) | |
| Solari et al. | Electrochemotherapy for cutaneous metastases: The IRCCS San Martino Hospital and National Cancer Research Institute of Genoa's experience | |
| Ahmad | Evaluating anti-oxidant potential of Callistemon viminalis leaves extracts and their compounds in STAT 3 pathway in liver cancer | |
| MIYAZAKI et al. | Clinical Appraisalof Hyperthermic Treatment Combined with Low Dose of Gemcitabine Hydrochlo Ride for the Unresectable Pancreas Cancer | |
| Xu et al. | Connection between epithelial-mesenchymal transition and cancer stem cells and the potential therapeutic strategies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160530 |